Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -112.70K | -112.70K | -1.52M | -1.52M | -939.70K |
| Total Depreciation and Amortization | 24.90K | 24.90K | 25.30K | 25.30K | 26.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -898.00K | -898.00K | 640.40K | 640.40K | 384.80K |
| Change in Net Operating Assets | -197.30K | -197.30K | 227.40K | 227.40K | 63.20K |
| Cash from Operations | -1.18M | -1.18M | -624.50K | -624.50K | -465.50K |
| Capital Expenditure | 0.00 | 0.00 | -7.20K | -7.20K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.60K | 2.60K | -- | -- | -- |
| Cash from Investing | 2.60K | 2.60K | -7.20K | -7.20K | 0.00 |
| Total Debt Issued | 475.00K | 475.00K | 625.00K | 625.00K | -641.10K |
| Total Debt Repaid | -168.40K | -168.40K | -50.00K | -50.00K | -50.00K |
| Issuance of Common Stock | 2.48M | 2.48M | -- | -- | 1.19M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 14.80K | 14.80K | -14.80K | -14.80K | -- |
| Cash from Financing | 2.80M | 2.80M | 560.20K | 560.20K | 500.00K |
| Foreign Exchange rate Adjustments | 3.00K | 3.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.63M | 1.63M | -71.50K | -71.50K | 34.50K |